Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NioDerm is an autologous dermo-epidermal substitute developed by Laboratorio Pablo Cassará as an advanced tissue-engineered therapy for the treatment of complex wounds and various skin conditions. The product is designed to replace or regenerate damaged skin using a bilayered structure composed of the patient's own cells, typically including keratinocytes and fibroblasts expanded in vitro. By utilizing autologous tissue, NioDerm aims to minimize the risk of graft rejection and promote physiological healing and integration at the wound site. It is categorized under the company's 'Terapias de Avanzada' (Advanced Therapies) division and is intended for surgical application or topical grafting in clinical settings where traditional skin repair methods are insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NioDerm.